Atwater Thomas, Cook Christine M, Massion Pierre P
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Cornelius Vanderbilt Endowed Chair in Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Semin Respir Crit Care Med. 2016 Oct;37(5):670-680. doi: 10.1055/s-0036-1592314. Epub 2016 Oct 12.
The noninvasive diagnosis of lung cancer remains a formidable challenge. Although tissue diagnosis will remain the gold standard for the foreseeable future, questions pertaining to the risks and costs associated with invasive diagnostic procedures are of prime relevance. This review addresses new modalities for improving the noninvasive evaluation of suspicious lung nodules. Ultimately, the goal is to translate early diagnosis into early treatment. We discuss how biomarkers could assist in distinguishing benign from malignant nodules and aggressive from indolent tumors. The field of biomarkers is rapidly expanding and progressing, and efforts are well underway to apply molecular diagnostics to address the shortcomings of current lung cancer diagnostic tools.
肺癌的非侵入性诊断仍然是一项艰巨的挑战。尽管在可预见的未来，组织诊断仍将是金标准，但与侵入性诊断程序相关的风险和成本问题至关重要。本综述探讨了改善可疑肺结节非侵入性评估的新方法。最终目标是将早期诊断转化为早期治疗。我们讨论了生物标志物如何有助于区分良性与恶性结节，以及侵袭性与惰性肿瘤。生物标志物领域正在迅速扩展和发展，目前正在努力应用分子诊断来弥补当前肺癌诊断工具的不足。
